RFCA
DRNA

R&F Capital Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

R&F Capital Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$34K Buy
+10,020
New +$28.2K 0.01% 661

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

R&F Capital Advisors's DRNA Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2017: 10,020 shares worth $34K. The stake represents 0.01% of the portfolio and ranks #661 among its holdings.

45 funds tracked by Wall St. Rank hold DRNA as of Q1 2017.

  • R&F Capital Advisors held 10,020 shares of Dicerna Pharmaceuticals, Inc. worth $34K as of Q1 2017.
  • Dicerna Pharmaceuticals, Inc. was a new R&F Capital Advisors position in Q1 2017.
  • Dicerna Pharmaceuticals, Inc. made up 0.01% of R&F Capital Advisors's portfolio in Q1 2017, its #661 holding.
  • 45 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.